Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | 0.00 | 0.00 |
| FCF Yield | 0.00% | -20.13% | -44.03% | -23.94% |
| EV / EBITDA | 0.00 | -4.23 | -5.13 | -3.30 |
| Quality | ||||
| ROIC | 0.00% | -317.57% | -196.46% | 4,972.32% |
| Gross Margin | 0.00% | 70.78% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.59 | 0.36 | -0.63 | -2.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,187,609.27% | 554,000.48% | 554,000.48% | 554,000.48% |
| Free Cash Flow Growth | 0.00% | 28.24% | -51.21% | 35.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -1.29 | -2.08 | -1.17 |
| Interest Coverage | 0.00 | -319.12 | -669.74 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.11 | 0.01 | 0.01 |
| Cash Conversion Cycle | 0.00 | -1,150.79 | -12,869.62 | -28,384.48 |